(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 0.84% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.
Charles River Laboratories International's revenue in 2026 is $4,027,044,000.On average, 18 Wall Street analysts forecast CRL's revenue for 2026 to be $187,227,966,510, with the lowest CRL revenue forecast at $179,858,303,820, and the highest CRL revenue forecast at $197,873,034,840. On average, 18 Wall Street analysts forecast CRL's revenue for 2027 to be $191,033,217,180, with the lowest CRL revenue forecast at $181,255,167,990, and the highest CRL revenue forecast at $204,472,013,850.
In 2028, CRL is forecast to generate $199,896,079,500 in revenue, with the lowest revenue forecast at $188,817,501,600 and the highest revenue forecast at $212,467,857,030.